No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BNOX Bionomics
- 0.966
- +0.019+2.05%
Close Apr 25 16:00 ET
- 0.956
- -0.011-1.09%
Post 16:55 ET
10.33MMarket Cap-358P/E (TTM)
1.000High0.918Low73.58KVolume0.940Open0.947Pre Close71.23KTurnover1.04%Turnover RatioLossP/E (Static)10.69MShares6.41052wk High0.55P/B6.85MFloat Cap0.87052wk Low--Dividend TTM7.09MShs Float22.000Historical High--Div YieldTTM8.71%Amplitude0.870Historical Low0.968Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersOneMedNet (NASDAQ:ONMD) shares moved upwards by 75.9% to $1.39 during Tuesday's after-market session. The market value of their outstanding shares is at $44.8 million. Aesthetic Medical Intl (N
Buy Rating Affirmed for Bionomics' BNC210 Following Promising PTSD Study Results
Bionomics's BNC210 Shows Promise for PTSD Treatment: A Buy Rating Analysis
Bionomics Reveals Detailed Data From PTSD Trial, Stock Soars
Thursday, Bionomics Limited (NASDAQ:BNOX) released a full dataset analysis from its Phase 2b ATTUNE trial of BNC210 in patients with post-traumatic stress disorder (PTSD).In September 2023, Bionomics
Express News | Bionomics Shares Are Trading Higher After the Company Disclosed Results of Phase 2b ATTUNE Trial of BNC210 in Post-traumatic Stress Disorder
Express News | Bionomics Disclosed Results Of The Full Dataset Analysis From ATTUNE Phase 2b Trial Of BNC210 In Patients With Post-Traumatic Stress Disorder
Comments
Gap up rule in effect!
$Bionomics(BNOX.US$ Watching to see if it holds true! Most times it does. So at this point I believe this is done! JMO
Mark the dates
$Bionomics(BNOX.US$ BNC210 demonstrated a statistically significant improvement in post-traumatic stress disorder (PTSD) symptom severity with a clinically meaningful effect size suggesting a potential advantage over approved medications.
BNC210's emerging safety and tolerability profile continues to support its differentiation over approved, available, and experimental psychoactive treatments.
Bionomics will meet with the U.S. Food & Drug Administration (FDA) to discuss BNC210's...
BNC210's emerging safety and tolerability profile continues to support its differentiation over approved, available, and experimental psychoactive treatments.
Bionomics will meet with the U.S. Food & Drug Administration (FDA) to discuss BNC210's...
1
News
$Bionomics(BNOX.US$ Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder
5 MINUTES AGO, 6:00 AM EDT
VIA GLOBENEWSWIRE
5 MINUTES AGO, 6:00 AM EDT
VIA GLOBENEWSWIRE
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg